



(12) Translation of
European patent specification

(11) NO/EP 3197867 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 207/48 (2006.01)
A61K 31/095 (2006.01)
A61K 31/40 (2006.01)
C07D 207/30 (2006.01)
C07D 207/335 (2006.01)
C07D 207/36 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2019.02.11
(80)	Date of The European Patent Office Publication of the Granted Patent	2018.11.14
(86)	European Application Nr.	16786741.5
(86)	European Filing Date	2016.04.27
(87)	The European Application's Publication Date	2017.08.02
(30)	Priority	2015.04.27, KR, 20150058712 2016.02.03, KR, 20160013588
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Validation States:	MA
(73)	Proprietor	Daewoong Pharmaceutical Co., Ltd., 244, Galmachi-ro Jungwon-gu Seongnam-si, Gyeonggi-do 13211, Sør-Korea
(72)	Inventor	LEE, Chun Ho, 103-1203, 57 Seochojungang-ro 24-gilSeocho-gu, Seoul 06603, Sør-Korea LEE, Seung Chul, B-1604 22 Neuti-roBundang-gu, Seongnam-siGyeonggi-do 13558, Sør-Korea LEE, Yeon Im, 108-801, 283 Dongbaekjukjeon-daeroGiheung-gu, Yongin-siGyeonggi-do 16995, Sør-Korea EOM, Deok Ki, 2311-1703, 96 Dongbaek 7-roGiheung-gu, Yongin-siGyeonggi-do 17003, Sør-Korea HAN, Mi Ryeong, 128-1606, 135 Gwanak-daeroDongan-gu, Anyang-siGyeonggi-do 13922, Sør-Korea KOH, Eun Ji, 301, 288 Pogok-roPogok-eupCheoin-gu, Yongin-siGyeonggi-do 17028, Sør-Korea
(74)	Agent or Attorney	BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

(54)	Title	NOVEL 4-METHOXY PYRROLE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
------	-------	--

(56) References

Cited:


KR-A- 20070 060 133, WO-A1-2014/075575, MARCO BLANGETTI ET AL: "LIC-KOR-Promoted Synthesis of Alkoxydienyl Amines: An Entry to 2,3,4,5-Tetrasubstituted Pyrroles", ORGANIC LETTERS, vol. 11, no. 17, 3 September 2009 (2009-09-03), pages 3914-3917, XP055363579, ISSN: 1523-7060, DOI: 10.1021/ol9015018, CA-A1- 2 891 523, JP-A- 2010 520 153, EP-A1- 1 803 709, HARUYUKI NISHIDA ET AL: "Discovery, synthesis, and biological evaluation of novel pyrrole derivatives as highly selective potassium-competitive acid blockers", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 20, no. 12, 14 April 2012 (2012-04-14), pages 3925-3938, XP055080139, ISSN: 0968-0896, DOI: 10.1016/j.bmc.2012.04.014, KR-A- 20110 091 826, YASUYOSHI ARIKAWA ET AL: "Synthetic studies of five-membered heteroaromatic derivatives as potassium-competitive acid blockers (P-CABs)", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 25, no. 10, 6 April 2015 (2015-04-06) , pages 2037-2040, XP002772323, DOI: 10.1016/j.bmcl.2015.03.094, BLANGETTI, M. ET AL.: 'LIC-KOR-Promoted Synthesis of Alkoxydienyl Amines: An Entry to 2, 3, 4, 5-Tetrasubstituted Pyrroles' ORGANIC LETTERS vol. 11, no. 17, 2009, pages 3914 - 3917, XP055363579

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Forbindelse representert ved følgende kjemiske formel 1 eller et farmasøytisk akseptabelt salt derav:

[Kjemisk formel 1]



5

i Kjemisk formel 1,

R₁, R₂ og R₃ er hver uavhengig hydrogen eller halogen, med det forbehold at R₁, R₂ og R₃ ikke kan være hydrogen samtidig, og

R₄ og R₅ er hver uavhengig hydrogen, halogen, C₁₋₄ alkyl, C₁₋₄ alkoksy, C₁₋₄ haloalkyl, eller C₁₋₄ haloalkoksy, med det forbehold at R₄ og R₅ ikke kan være hydrogen samtidig.

10

2. Forbindelse eller et farmasøytisk akseptabelt salt derav ifølge krav 1, hvor R₁, R₂ og R₃ er hver uavhengig hydrogen, fluor, eller klor, med det forbehold at R₁, R₂ og R₃ ikke kan være hydrogen samtidig.

15

3. Forbindelse eller et farmasøytisk akseptabelt salt derav ifølge krav 1, hvor R₄ og R₅ er hver uavhengig hydrogen, klor, fluor, metyl, trifluormetyl, metoksy, eller difluormetoksy, med det forbehold at R₄ og R₅ ikke kan være hydrogen samtidig.

20

4. Forbindelse eller et farmasøytisk akseptabelt salt derav ifølge krav 1, hvor R₁ er halogen, og R₂ og R₃ er hver uavhengig hydrogen, eller halogen.

5. Forbindelse eller et farmasøytisk akseptabelt salt derav ifølge krav 1, hvor R₁ er fluor, og R₂ og R₃ er hver uavhengig hydrogen, fluor, eller klor, eller R₁ er klor, og R₂ og R₃ er hydrogen.

25


6. Forbindelse eller et farmasøytisk akseptabelt salt derav ifølge krav 1, hvor R₄ er halogen, og R₅ er klor, fluor, metyl, trifluormetyl, metoksy, eller difluormetoksy, eller R₄ og R₅ er hver uavhengig klor, eller fluor.

30

7. Forbindelse eller et farmasøytisk akseptabelt salt derav ifølge krav 1, hvor R_1 er fluor, og R_2 og R_3 er hver uavhengig hydrogen, eller fluor, R_4 er hydrogen, og R_5 er klor, eller trifluormetyl.


- 5 8. Forbindelse eller et farmasøytisk akseptabelt salt derav ifølge krav 1, hvor forbindelsen er valgt fra gruppen representert ved de følgende Kjemiske formler 1-2 til 1-4:

[Kjemisk formel 1-2]




10

[Kjemisk formel 1-3]



[Kjemisk formel 1-4]



- 15 i Kjemiske formler 1-2 til 1-4,
 R_1 til R_5 er som definert i krav 1.

9. Forbindelse eller et farmasøytisk akseptabelt salt derav ifølge krav 1, hvor forbindelsen er valgt fra gruppen bestående av følgende forbindelser:

- 20 1) 1-(5-(2-fluorfenyl)-4-metoksy-1-((3-klorfenyl)sulfonyl)-1H-pyrrol-3-yl)-N-metylmetyanamin;

- 2) 1-(5-(2-fluorfenyl)-4-metoksy-1-((3-(trifluormetyl)fenyl)sulfonyl)-1H-pyrrol-3-yl)-N-metylmetanamin;
- 3) 1-(5-(2-fluorfenyl)-4-metoksy-1-((3-metoksyfenyl)sulfonyl)-1H-pyrrol-3-yl)-N-metylmetanamin;
- 5 4) 1-(5-(2-fluorfenyl)-4-metoksy-1-((3-difluormetoksyfenyl)sulfonyl)-1H-pyrrol-3-yl)-N-metylmetanamin;
- 5) 1-(5-(2-klorfenyl)-4-metoksy-1-((3-metoksyfenyl)sulfonyl)-1H-pyrrol-3-yl)-N-metylmetanamin;
- 6) 1-(5-(2-fluor-4-klorfenyl)-4-metoksy-1-((3-klorfenyl)sulfonyl)-1H-pyrrol-3-yl)-N-metylmetanamin;
- 10 7) 1-(5-(2-fluor-4-klorfenyl)-4-metoksy-1-((3-(trifluormetyl)fenyl)sulfonyl)-1H-pyrrol-3-yl)-N-metylmetanamin;
- 8) 1-(5-(2,4-difluorfenyl)-1-((3-fluorfenyl)sulfonyl)-4-metoksy-1H-pyrrol-3-yl)-N-metylmetanamin;
- 15 9) 1-(5-(2,4-difluorfenyl)-1-((3-(trifluormetyl)fenyl)sulfonyl)-4-metoksy-1H-pyrrol-3-yl)-N-metylmetanamin;
- 10) 1-(5-(2,4-difluorfenyl)-1-((3-metylfenyl)sulfonyl)-4-metoksy-1H-pyrrol-3-yl)-N-metylmetanamin;
- 11) 1-(5-(2,4-difluorfenyl)-1-((3-metoksyfenyl)sulfonyl)-4-metoksy-1H-pyrrol-3-yl)-N-metylmetanamin;
- 20 12) 1-(5-(2,4-difluorfenyl)-1-((3-difluormetoksyfenyl)sulfonyl)-4-metoksy-1H-pyrrol-3-yl)-N-metylmetanamin;
- 13) 1-(5-(2,6-difluorfenyl)-1-((3-fluorfenyl)sulfonyl)-4-metoksy-1H-pyrrol-3-yl)-N-metylmetanamin;
- 25 14) 1-(5-(2,6-difluorfenyl)-1-((3-klorfenyl)sulfonyl)-4-metoksy-1H-pyrrol-3-yl)-N-metylmetanamin;
- 15) 1-(5-(2,6-difluorfenyl)-1-((3-(trifluormetyl)fenyl)sulfonyl)-4-metoksy-1H-pyrrol-3-yl)-N-metylmetanamin;
- 16) 1-(5-(2,6-difluorfenyl)-1-((3-metylfenyl)sulfonyl)-4-metoksy-1H-pyrrol-3-yl)-N-metylmetanamin;
- 30 17) 1-(5-(2,6-difluorfenyl)-1-((3-metoksyfenyl)sulfonyl)-4-metoksy-1H-pyrrol-3-yl)-N-metylmetanamin;
- 18) 1-(5-(2,6-difluorfenyl)-1-((3-klor-4-fluorfenyl)sulfonyl)-4-metoksy-1H-pyrrol-3-yl)-N-metylmetanamin;
- 35 19) 1-(5-(2,6-difluorfenyl)-1-((3,4-difluorfenyl)sulfonyl)-4-metoksy-1H-pyrrol-3-yl)-N-metylmetanamin;

- 20) 1-(5-(2-fluor-6-klorfenyl)-1-((3-fluorfenyl)sulfonyl)-4-metoksy-1H-pyrrol-3-yl)-N-metylmetanamin;
- 21) 1-(5-(2-fluor-6-klorfenyl)-1-((3-klorfenyl)sulfonyl)-4-metoksy-1H-pyrrol-3-yl)-N-metylmetanamin;
- 5 22) 1-(1-((3-fluorfenyl)sulfonyl)-4-metoksy-5-(2,4,6-trifluorfenyl)-1H-pyrrol-3-yl)-N-metylmetanamin;
- 23) 1-(1-((3-klorfenyl)sulfonyl)-4-metoksy-5-(2,4,6-trifluorfenyl)-1H-pyrrol-3-yl)-N-metylmetanamin;
- 24) 1-(1-((3-trifluormetylfenyl)sulfonyl)-4-metoksy-5-(2,4,6-trifluorfenyl)-1H-pyrrol-3-yl)-N-metylmetanamin;
- 10 25) 1-(1-((3-metoksyfenyl)sulfonyl)-4-metoksy-5-(2,4,6-trifluorfenyl)-1H-pyrrol-3-yl)-N-metylmetanamin;
- 26) 1-(1-((3,4-difluorfenyl)sulfonyl)-4-metoksy-5-(2,4,6-trifluorfenyl)-1H-pyrrol-3-yl)-N-metanaminn;
- 15 27) 1-(1-((3-fluorfenyl)sulfonyl)-4-metoksy-5-(2,3,6-trifluorfenyl)-1H-pyrrol-3-yl)-N-metylmetanamin;
- 28) 1-(1-((3-klorfenyl)sulfonyl)-4-metoksy-5-(2,3,6-trifluorfenyl)-1H-pyrrol-3-yl)-N-metylmetanamin;
- 29) 1-(1-((3-trifluormetylfenyl)sulfonyl)-4-metoksy-5-(2,3,6-trifluorfenyl)-1H-pyrrol-3-yl)-N-metylmetanamin;
- 20 30) 1-(1-((3-metoksyfenyl)sulfonyl)-4-metoksy-5-(2,3,6-trifluorfenyl)-1H-pyrrol-3-yl)-N-metylmetanamin;
- 31) 1-(5-(2,5-difluorfenyl)-1-((3-fluorfenyl)sulfonyl)-4-metoksy-1H-pyrrol-3-yl)-N-metylmetanamin;
- 25 32) 1-(5-(2,5-difluorfenyl)-1-((3-trifluormetylfenyl)sulfonyl)-4-metoksy-1H-pyrrol-3-yl)-N-metylmetanamin; og
- 33) 1-(5-(2,5-difluorfenyl)-1-((3-metoksyfenyl)sulfonyl)-4-metoksy-1H-pyrrol-3-yl)-N-metylmetanamin.

30 10. Forbindelse eller et farmasøytisk akseptabelt salt derav ifølge krav 1, hvor det farmasøytisk akseptable saltet er hydroklorid eller fumaratsalt.

11. Farmasøytisk sammensetning for anvendelse i forebygging og behandling av gastrointestinale skader som skyldes gastrointestinale sår, gastritt, refluksøsofagitt eller H. pylori, omfattende forbindelsen eller det farmasøytisk akseptable salt derav ifølge et hvilket som helst av kravene 1 til 10.

35

12. Farmasøytisk sammensetning for anvendelse i forebygging og behandling av 5-HT-reseptormedierte eller muskariniske acetylkolinreseptormedierte sykdommer valgt fra depresjon, manisk depresjon, schizofreni, autisme, obsessiv-kompulsiv nevrose, angstlidelse, migrene, hypertensjon, spiseforstyrrelse, irritabelt tarmsyndrom (IBS), magesår, diabetisk nevropati, astma, og overaktiv blære, omfattende forbindelsen eller det farmasøytisk akseptable salt derav ifølge et hvilket som helst av kravene 1 til 10.